Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study
Tara Moore, Ashfaq Afridi, Nurul H Aminudin, Cathy Gibbons, Orna Grant, Hana Fucikova, Carmel Maria Moore · 2026
Read Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study by Tara Moore, Ashfaq Afridi, Nurul H Aminudin, Cathy Gibbons, Orna Grant, Hana Fucikova, Carmel Maria Moore (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13217116.txt.
Description
Tara Moore and six co-authors studied a national vaccine-like program in Ireland in 2026. Babies got nirsevimab, an antibody shot that guards against RSV, a virus that causes bronchiolitis and fills children's wards each winter. The program ran from September 2024 to February 2025, was free at maternity units, and reached 83 percent of newborns.
Very sick babies often need transfer to intensive care by special transport teams. The team checked whether transport trips for bronchiolitis fell after the program began. National data already showed steep drops in RSV cases, ward stays, and intensive care stays. Fewer transfers would ease pressure on ambulances, hospitals, and families during the winter peak.
Catalog record
| CREATOR | Tara Moore, Ashfaq Afridi, Nurul H Aminudin, Cathy Gibbons, Orna Grant, Hana Fucikova, Carmel Maria Moore |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |